IAG’s Scientific Leadership Team Talks AI and Imaging in Drug Development
Dr. Olga Kubassova and Dr. Diana Dupont-Roettger will be presenting on the topic of AI and Imaging in Drug Development in a webinar organised in collaboration with Izmir Katip Celebi University Medical School.
Title: AI and Imaging in Drug Development
Date: 6 May 2021
For more information, please contact firstname.lastname@example.org
Dr Diana Dupont-Roettger, IAG’s Chief Scientific Alliance Officer
Medical computer scientist by background, with strong experience in world-class academic research, biotechnology industry, pharma and investment. 10+ years of experience in the strategic use of medical imaging in the assessment of drug efficacy, trial conceptualizing, trial design and de-risking. Actively working with biotech companies to bridge the gap between academic research and their strategy for commercialization.
Dr Olga Kubassova, IAG’s CEO
Dr. Olga Kubassova is a mathematician by background with MS in Mathematics from St. Petersburg State University, Russia, MS in Information Technology from Lappeenranta University of Technology, Finland and a PhD in Computer Science from the University of Leeds, UK.
Dr. Olga Kubassova is the founding scientist and CEO of IAG, Image Analysis Group, an imaging expert company. She started IAG straight after her PhD with an idea to bring the best of mathematics and computer science to optimize clinical development process while using imaging derived biomarkers to reliably and objectively assess efficacy of a novel drug.
Today IAG is a recognized partner to many blue-chip pharma companies in rheumatology, oncology and neurology. Since completing her PhD research in the area of MRI algorithm development for musculoskeletal disorders, Olga has been a significant contributor to the development of MRI as a clinical research and diagnostic tool in rheumatoid arthritis, osteoarthritis and other inflammatory joint diseases. She has co-authored over 60 articles, 7 book chapters and a number of abstracts that have built a significant evidence base for the medical imaging as a sensitive and objective biomarker for the assessment of various diseases and as an early measure of efficacy of new drugs. Olga is an active researcher, scientific adviser to the UK government and EU funding bodies, inc. European Commission, Innovative Medicines Initiative; she is an editor and reviewer of several scientific journals.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: email@example.com
Follow the Company: Linkedin